Literature DB >> 9176120

Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.

N K Rushmere1, S Tomlinson, B P Morgan.   

Abstract

This study reports the expression and functional characterization of the rat analogue of the human complement regulatory molecule CD59. We here describe the expression in chinese hamster ovary (CHO) cells of rat CD59 and a modified rat CD59 in which an N-glycosylation site at Asn-16 has been deleted by point mutation. The complement-inhibiting capacity of these two forms of rat CD59 has been analysed and compared. Expressed rat CD59 efficiently inhibited complement lysis of CHO cells when rat serum was used as a source of complement and also inhibited lysis by complement from all other species tested, confirming that rat CD59 displayed little or no species restriction of activity. Blocking of expressed rat CD59 with a monoclonal antibody abrogated the inhibition of lysis for all sources of complement, confirming that the expressed molecule was responsible for the protection. The glycosylation mutant had a much reduced molecular weight on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (12,000 MW as compared with 20,000-28,000 MW for unmutated), confirming that it was unglycosylated. However, the glycosylation mutant had complement-inhibitory activity which was at least as potent as that of the unmutated molecule, demonstrating that the large, N-linked carbohydrate moiety was not required for function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176120      PMCID: PMC1456686          DOI: 10.1046/j.1365-2567.1997.00200.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.

Authors:  T Hüsler; D H Lockert; K M Kaufman; J M Sodetz; P J Sims
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

2.  Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.

Authors:  N K Rushmere; R A Harrison; C W van den Berg; B P Morgan
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

3.  Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.

Authors:  C P Chang; T Hüsler; J Zhao; T Wiedmer; P J Sims
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

4.  Enhancement of the complement regulatory function of CD59 by site-directed mutagenesis at the N-glycosylation site.

Authors:  T Akami; K Arakawa; M Okamoto; K Akioka; I Fujiwara; I Nakai; M Mitsuo; R Sawada; M Naruto; T Oka
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

Review 5.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted.

Authors:  C W van den Berg; B P Morgan
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

7.  Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59.

Authors:  P A van der Merwe; A N Barclay; D W Mason; E A Davies; B P Morgan; M Tone; A K Krishnam; C Ianelli; S J Davis
Journal:  Biochemistry       Date:  1994-08-23       Impact factor: 3.162

8.  Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.

Authors:  R P Rother; S A Rollins; J Mennone; A Chodera; S A Fidel; M Bessler; P Hillmen; S P Squinto
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

9.  CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.

Authors:  E Menu; B C Tsai; A L Bothwell; P J Sims; B E Bierer
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

10.  Structure of a soluble, glycosylated form of the human complement regulatory protein CD59.

Authors:  C M Fletcher; R A Harrison; P J Lachmann; D Neuhaus
Journal:  Structure       Date:  1994-03-15       Impact factor: 5.006

View more
  7 in total

1.  Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.

Authors:  S Chen; T Caragine; N K Cheung; S Tomlinson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic β-cells by interaction with SNARE proteins.

Authors:  Anna M Blom; Ben C King; Ewelina Golec; Rebecca Rosberg; Enming Zhang; Erik Renström
Journal:  FASEB J       Date:  2019-08-14       Impact factor: 5.191

4.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

5.  GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.

Authors:  K D Whitney; J O McNamara
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

6.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

7.  Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies.

Authors:  S M Hanna; G T Williams; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.